Chair & Introduction:Dr. Christian Zschocke, Managing Partner,
Morgan Lewis & Bockius LLP

25 Years In: Did Biotechnology Deliver?
Dr. Hans A. Küpper, Partner,
Global Life Science Ventures GmbH

Chair: Adi Seffer, Partner,
Morgan Lewis & Bockius LLP

Financing Biotech Companies in Europe
Frances Bornstein, Vice President, Head of Issuers and Investor Relations,
SWX Swiss Exchange

Panel Discussion: Innovative Partnering Models
This session will look at innovative ways in which pharmas & biotechs, and now VCs, are working together. Topics for discussion will include: Which recent alliances / partnerships are proving most successful and why? Will VCs become more active in creating these deals, and to what profit? Is big pharma assuming the role of ‘end-customer’ over capital markets – and what impact will this continue to have on partnering models?
Chair: Dr. Samir Master M.D., Vice President, Business Development & Licensing, Head Biotechnology & Speciality Pharmaceuticals, Novartis Pharma, AG
• Dr. Jonathan. D. Turner, Head of Corporate Department Business Development,
Boehringer Ingelheim
• Dr. Olaf Bartsch, Vice President Business Development Europe, Genzyme GmbH
• Chris Britten, Director, GSK Ventures, GlaxoSmithKline
• Simon Sturge, Chief Executive Officer, Vernalis
• Nick Lowcock, Managing Director, Warburg Pincus International LLC

Workshop I: Immunology/Oncology Workshop II: Post-Genomics: Pharmacogenomics & Proteomics

Workshop III: Medical Devices/ Diagnostics Workshop IV: Bioinformatics, SNP, Array Technology

Workshop V: Therapeutics Chaired by: Hanns-Peter Wiese, Partner, Global Life Science Ventures GmbH

Panel Discussion: Pharma Partnerships as a Means of Raising Finance
This session looks at how the recent economic downturn in the global financial markets has resulted in a longer "trough", causing private equity investors, who have traditionally been the life-blood of biotechs, to re-think the whole biotech model. Since the need for partnering continues to increase and pharma companies are financially much stronger than equity investors, deals currently represent a unique financing tool.
Chair: Dimitri F. Dimitriou, Chief Executive Officer, DyoDelta Biosciences Ltd
• Dr. Chris Henderson, Director Global Licensing, AstraZeneca
• Chris Piggott, Senior Director, Global Business Development, Aventis
• Spiro Rombotis, CEO, Cyclacel
• Michel Hubert, Vice President, Business Development, Transgene
• N. Peter Kostopulos, Partner, Womble Carlyle Sandridge & Rice, PPLC and Chariman, Strategic Alliance Committee of the Licensing Executives Society

Meeting Europe's Challenge
Mark Clement, Chief Executive,
Merlin Biosciences Limited

International Perspectives on Venture Investing
This session will look at the development of regional life science markets: Europe and the U.S. Speakers from these regions will discuss:
- investment activities & trends in their relevant markets
- identifying sector hotspots
- valuation
Chair: Stan Yakatan, Chairman, Katan Associates
Speakers:
• Dr. Francois Thomas, Atlas Venture
• Prof. Jesper Zeuthen, Managing Director, BankInvest Bio Venture
• Heinz Michael Meier, Chief Executive, Bayern Kapital GmbH
• Dr. Andreas Wicki, CEO, HBM Partners
• Neil Cohen, Partner, Israel Seed Partners
• Ben Bronstein, Managing Director, Zero Stage Capital

Investor Panel: Valuating Biotech
This session will look at the importance of valuating Biotech companies, particularly at an early-stage, and assess the long-term impact a valuation can have on a company’s prospects for raising finance and attracting partners.
Chair: Dr. Marion Dörner, Principal, Earlybird GmbH & Co. KG
• Dr. Holger Reithinger, Director, 3i Deutschland GbmH
• Dr. Regina Hodits, Principal, Apax Partners
• Dr. Alexander Asam, Partner, DVC Deutsche Venture Capital
• Adi Seffer, Partner, Morgan Lewis & Bockius LLP

Workshop I: Immunology/Oncology

WorkshopII: Therapeutics